Membranous glomerulonephritis

This phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injectio…

This study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…

This early-stage study tested a new drug called VB119 in 6 adults with primary membranous nephropathy, a kidney disease. The main goal was to check safety and how the body handles the drug, not to cure the disease. The study was terminated early, so results are limited.

This study looked at whether adding cyclosporine to rituximab is more effective than rituximab alone for treating idiopathic membranous nephropathy, a kidney disease that causes protein leakage. Only 12 adults with severe proteinuria took part before the study ended early. The go…